云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀-B

午间休市 12-19 12:30:01

48.000

-1.700

-3.42%

最高49.400	最低47.550	成交量181.90万
今开49.400	昨收49.700	日振幅3.72%
总市值156.48亿	流通市值156.48亿	总股本3.26亿
成交额8,785万	换手率0.56%	流通股本3.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀-B","latestPrice":48,"timestamp":1734582601061,"preClose":49.7,"halted":0,"volume":1819000,"delay":0,"floatShares":326000000,"shares":326000000,"eps":-2.893581,"marketStatus":"午间休市","marketStatusCode":3,"change":-1.7,"latestTime":"12-19 12:30:01","open":49.4,"high":49.4,"low":47.55,"amount":87849312,"amplitude":0.037223,"askPrice":48.05,"askSize":3500,"bidPrice":48,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-3.508470731917077,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734584400000},"adr":0,"listingDate":1602172800000,"adjPreClose":49.7,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.994485,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"2492198509","title":"交银国际：医保工作会议再提丙类目录和支持商保发展 关注政策宽松相关机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2492198509","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492198509?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:31","pubTimestamp":1734571909,"startTime":"0","endTime":"0","summary":"全国医疗保障工作会议首提探索形成丙类目录。全国医疗保障工作会议共提出八大工作重点，其中多项措施明确支持商保发展。其中第五条“强化医保战略购买，赋能医药产业创新发展”指出，要“支持引导普惠型商业健康保险及时将创新药品纳入报销范围，研究探索形成丙类药品目录，并逐步扩大至其他符合条件的商业健康保险”。预计2025年，商保将有望迎来进一步发展，为解决创新药上市后的支付问题提供新的思路。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1515","BK1521","LU1794554557.SGD","BK1583","LU0417516571.SGD","09926","IE00BPRC5H50.USD","01952","BK1191","LU2488822045.USD","LU0348783233.USD","BK1147","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK1589","BK1161","LU1720050803.USD","LU0348784397.USD","01177","BK1574","03329"],"gpt_icon":0},{"id":"2492891167","title":"【券商聚焦】交银国际预计2025年商保将有望进一步发展 协助解决创新药支付问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2492891167","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492891167?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:59","pubTimestamp":1734569982,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际预计2025年商保将有望进一步发展，协助解决创新药支付问题。同时，丙类目录+商保差异化发展的创新支付机制或缓解创新药械企业面临的进院难、报销支付难问题。近期医药板块在大幅震荡后有所回落，考虑到板块估值仍处于历史底部、叠加后续财政、医保/商保利好政策出台+流动性改善，该行认为仍有进一步修复空间。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK1589","LU0417516571.SGD","LU1720050803.USD","IE00B543WZ88.USD","09926","01177","BK1515","BK1521","159992","02096","06978","01952","BK1583","LU1794554557.SGD","BK1191","LU0348783233.USD","BK1147","LU0348784397.USD","BK1161","03329","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2492232192","title":"云顶新耀宣布全球首个IgA肾病对因治疗药物耐赋康®开出中国香港首张处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2492232192","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492232192?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:30","pubTimestamp":1734568200,"startTime":"0","endTime":"0","summary":"耐赋康是全球首个获得美国食品药品监督管理局和欧洲药品管理局完全批准的IgA肾病治疗药物。作为全球首个对因治疗IgA肾病的药物，耐赋康能较有效地稳定肾功能，降低蛋白尿、血尿。IgA肾病在亚洲高发，也是中国青壮年肾衰的主要病因之一。目前，在云顶新耀的授权区域内，耐赋康的可及性在得到持续扩大，已经相继在中国澳门、中国香港、新加坡、中国台湾与韩国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4582660_ZH82660_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0149725797.USD","IE00BHPRN162.USD","BK1161","LU0267386448.USD","IE00BKVL7J92.USD","CMC","IE00BZ1G4Q59.USD","BK4006","LU1363072403.SGD","LU0170899867.USD","01952","IE00B1BXHZ80.USD","BK1583","LU0882574139.USD","LU0971096721.USD","BK1574"],"gpt_icon":0},{"id":"2492579982","title":"云顶新耀-B(01952)上涨2.14%，报50.05元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492579982","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492579982?lang=zh_cn&edition=full","pubTime":"2024-12-17 15:47","pubTimestamp":1734421643,"startTime":"0","endTime":"0","summary":"12月17日，云顶新耀-B(01952)盘中上涨2.14%，截至15:47，报50.05元/股，成交3.0亿元。云顶新耀有限公司是一家专门从事创新药和疫苗的研发、临床开发、制造和商业化的生物制药公司，主要服务大中华区和其他亚洲市场。公司在药物和疫苗的自主研发上表现优异，同时在肾科疾病、mRNA平台、感染性和传染性疾病、自身免疫性疾病等领域已建立全球同类首创或者同类最佳的药物和疫苗组合。截至2024年中报，云顶新耀-B营业总收入3.02亿元、净利润-6.32亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/17154746469493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2492198298","title":"云顶新耀：伊曲莫德被纳入广东省粤港澳大湾区临床急需药械目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2492198298","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492198298?lang=zh_cn&edition=full","pubTime":"2024-12-17 15:35","pubTimestamp":1734420955,"startTime":"0","endTime":"0","summary":"本报讯（记者张文湘见习记者金婉霞）12月16日，云顶新耀医药科技有限公司（下称：云顶新耀）宣布，其伊曲莫德被纳入广东省粤港澳大湾区内地九市临床急需港澳药品医疗器械目录（2024年）（以下简称：临床急需药械目录）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412173270804874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1574","BK1161","01952"],"gpt_icon":0},{"id":"2492154958","title":"云顶新耀宣布中国国家药品监督管理局正式受理伊曲莫德（VELSIPITY®）用于治疗中重度活动性溃疡性结肠炎的新药上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154958","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492154958?lang=zh_cn&edition=full","pubTime":"2024-12-17 12:34","pubTimestamp":1734410040,"startTime":"0","endTime":"0","summary":"上海2024年12月17日 /美通社/ -- 云顶新耀是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布中国国家药品监督管理局已正式受理伊曲莫德用于治疗中重度活动性溃疡性结肠炎患者的新药上市许可申请。云顶新耀也已在中国香港递交了伊曲莫德的新药上市许可申请并获得正式受理。伊曲莫德已于去年10月和今年2月先后在美国和欧盟获得新药上市批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4581404_ZH81404_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","LU0170899867.USD","LU0971096721.USD","01952","IE00BZ1G4Q59.USD","IE00BHPRN162.USD","IE00B1BXHZ80.USD","LU0149725797.USD","BK1574","LU1363072403.SGD","BK4006","LU0882574139.USD","IE00BKVL7J92.USD","CMC","BK1583","LU0267386448.USD"],"gpt_icon":0},{"id":"1177609472","title":"异动解读 | 云顶新耀-B(01952)盘中大涨6.33% 产品纳入国家医保目录前景看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1177609472","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177609472?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:58","pubTimestamp":1734400708,"startTime":"0","endTime":"0","summary":"医药生物科技公司云顶新耀(01952)盘中股价大涨6.33%,引发投资者关注。\n\n根据消息,云顶新耀旗下IgA肾病治疗药物耐赋康将于2025年1月1日起纳入新一版国家医保目录,成为目录中唯一一款针对IgA肾病的治疗药物。分析指出,耐赋康成功纳入医保,将在未来两年内掌握国内IgA肾病新药市场绝对优势,被市场看好其未来增长前景。\n\n同时,云顶新耀旗下另一自身免疫性疾病创新药伊曲莫德亦在本月开始向亚洲地区上市,标志着该公司产品线持续扩张,进军新的疾病领域及市场。产品管线不断丰富有望成为公司未来发展新动力,投资者对公司长期前景充满信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01952"],"gpt_icon":0},{"id":"2492672855","title":"云顶新耀-B早盘涨近6%% 月内累计涨幅已超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492672855","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492672855?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:55","pubTimestamp":1734400500,"startTime":"0","endTime":"0","summary":"　　云顶新耀-B早盘再上涨，月内累计涨幅已超50%。截至发稿，股价上涨5.61%，现报51.75港元，成交额1.25亿港元。　　新版国家医保药品目录将于2025年1月1日起正式生效，耐赋康首次参加医保谈判并成功纳入国家医保药品目录。耐赋康成功纳入医保目录，奠定了耐赋康在IgA肾病领域的先发优势，未来有望独占两年国内IgA肾病新药市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-17/doc-incztptx1872386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1574","BK1161","01952"],"gpt_icon":0},{"id":"2492674723","title":"港股异动 | 云顶新耀-B(01952)再涨近6%% 耐赋康未来有望独占两年国内IgA肾病新药市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2492674723","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492674723?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:46","pubTimestamp":1734400011,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀-B再涨近6%，月内累计涨幅已超50%。消息面上，新版国家医保药品目录将于2025年1月1日起正式生效，耐赋康首次参加医保谈判并成功纳入国家医保药品目录。西部证券指出，耐赋康是中国唯一获得IgA肾病适应症的治疗药物，也是国家医保药品目录中唯一针对IgA肾病适应症的治疗药物。耐赋康成功纳入医保目录，奠定了耐赋康在IgA肾病领域的先发优势，未来有望独占两年国内IgA肾病新药市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","BK1161","01952"],"gpt_icon":0},{"id":"2492822674","title":"云顶新耀-B盘中异动 急速拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492822674","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492822674?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:37","pubTimestamp":1734399447,"startTime":"0","endTime":"0","summary":"2024年12月17日早盘09时37分，云顶新耀-B股票出现波动，股价急速上涨5.00%。截至发稿，该股报51.450港元/股，成交量99.8585万股，换手率0.31%，振幅5.10%。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。云顶新耀-B股票所在的生物技术行业中，整体涨幅为0.02%。云顶新耀-B公司简介：云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093727ab7dc160&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093727ab7dc160&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","BK1161","01952"],"gpt_icon":0},{"id":"2491659958","title":"云顶新耀-B12月16日主力资金流入775万元 连续7日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2491659958","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491659958?lang=zh_cn&edition=full","pubTime":"2024-12-16 16:15","pubTimestamp":1734336916,"startTime":"0","endTime":"0","summary":"12月16日, 云顶新耀-B股价涨3.38%，报收49.00元，成交金额1.91亿元，换手率1.21%，振幅5.38%，量比0.81。云顶新耀-B今日主力资金净流入775万元，连续7日净流入，上一交易日主力净流入1454万元，今日环比减少46.70%。该股近5个交易日上涨2.61%，主力资金累计净流入4517万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入2.06亿元，其中净流入天数为14日。该股主力净额占比0.05%，港股市场排名82/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161530ab7bc859&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161530ab7bc859&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2491168635","title":"云顶新耀-B高开超3% 近日伊曲莫德在中国澳门的首张处方落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2491168635","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491168635?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:37","pubTimestamp":1734313020,"startTime":"0","endTime":"0","summary":"　　云顶新耀-B早盘高开，股价上涨3.27%，现报48.95港元，成交额2442.23万港元。　　近日，云顶新耀-B宣布伊曲莫德于12月11日在中国澳门镜湖医院开出首张处方，这也是伊曲莫德在云顶新耀亚洲授权区内获批后开出的首张处方，标志着这款自身免疫性疾病领域的重磅产品正式开始惠及亚洲患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-16/doc-inczrkur2983672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01952","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2491685231","title":"港股异动 | 云顶新耀-B(01952)高开近3% 近日伊曲莫德在中国澳门的首张处方落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2491685231","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491685231?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:26","pubTimestamp":1734312374,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀-B高开近3%，截至发稿，涨2.64%，报48.65港元，成交额116.76万港元。消息面上，近日，云顶新耀-B宣布伊曲莫德于12月11日在中国澳门镜湖医院开出首张处方，这也是伊曲莫德在云顶新耀亚洲授权区内获批后开出的首张处方，标志着这款自身免疫性疾病领域的重磅产品正式开始惠及亚洲患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01952","BK1161","BK1583"],"gpt_icon":0},{"id":"2491310789","title":"云顶新耀自免疫疾病产品伊曲莫德在中国澳门开出首张处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2491310789","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491310789?lang=zh_cn&edition=full","pubTime":"2024-12-13 15:35","pubTimestamp":1734075356,"startTime":"0","endTime":"0","summary":"近日，云顶新耀医药科技有限公司（下称：云顶新耀）宣布产品伊曲莫德于12月11日在中国澳门镜湖医院开出首张处方，这也是伊曲莫德在云顶新耀亚洲授权区内获批后开出的首张处方。公开资料显示，伊曲莫德于2024年4月份获得中国澳门特别行政区药物监督管理局正式批准，用于治疗16岁及以上中重度活动性溃疡性结肠炎（UC）患者，它是目前唯一在全球三期临床试验中证实对孤立性直肠炎有疗效的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412133267923913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1161","01952","BK1574"],"gpt_icon":0},{"id":"2490795648","title":"云顶新耀-B12月12日主力资金流入543万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2490795648","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490795648?lang=zh_cn&edition=full","pubTime":"2024-12-12 16:15","pubTimestamp":1733991310,"startTime":"0","endTime":"0","summary":"12月12日, 云顶新耀-B股价涨0.10%，报收48.35元，成交金额1.33亿元，换手率0.83%，振幅3.31%，量比0.45。云顶新耀-B今日主力资金净流入543万元，连续5日净流入，上一交易日主力净流入921万元，今日环比减少41.04%。近一年数据显示，该股主力连续5日净流入后，次日上涨概率为60.00%，平均涨幅为11.73%。该股近5个交易日上涨5.83%，主力资金累计净流入4398万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入1.75亿元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212161516ab71ddbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212161516ab71ddbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0},{"id":"2490844329","title":"云顶新耀：伊曲莫德在中国澳门的首张处方落地 正式惠及亚洲患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2490844329","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490844329?lang=zh_cn&edition=full","pubTime":"2024-12-12 10:23","pubTimestamp":1733970226,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2490831842","title":"交银国际：予内地医药行业“领先”评级 上海设百亿人民币并购基金有利加速行业整合","url":"https://stock-news.laohu8.com/highlight/detail?id=2490831842","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490831842?lang=zh_cn&edition=full","pubTime":"2024-12-12 10:20","pubTimestamp":1733970040,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研究报告称，予内地医药行业“领先”评级。上海市发布文件，提出设立100亿元人民币生物医药产业并购基金，以推动行业的创新发展和并购重组，该行认为有利于加速行业的整合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","09926","02096","01952"],"gpt_icon":0},{"id":"2490841900","title":"云顶新耀(01952)宣布伊曲莫德(VELSIPITY®)在中国澳门的首张处方落地 正式惠及亚洲患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2490841900","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490841900?lang=zh_cn&edition=full","pubTime":"2024-12-12 10:06","pubTimestamp":1733969198,"startTime":"0","endTime":"0","summary":"作为云顶新耀自身免疫性疾病领域的重磅产品，伊曲莫德亦于今年上半年陆续在中国澳门、新加坡获得新药上市批准。此外，云顶新耀也于近期在中国香港递交了伊曲莫德的新药上市许可申请，并获得正式受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1574","01952"],"gpt_icon":0},{"id":"2490492007","title":"云顶新耀-B(01952)上涨5.09%，报48.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490492007","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490492007?lang=zh_cn&edition=full","pubTime":"2024-12-11 13:14","pubTimestamp":1733894045,"startTime":"0","endTime":"0","summary":"12月11日，云顶新耀-B(01952)盘中上涨5.09%，截至13:14，报48.5元/股，成交1.3亿元。云顶新耀有限公司是一家专门从事创新药和疫苗的研发、临床开发、制造和商业化的生物制药公司，主要服务大中华区和其他亚洲市场。公司在药物和疫苗的自主研发上表现优异，同时在肾科疾病、mRNA平台、感染性和传染性疾病、自身免疫性疾病等领域已建立全球同类首创或者同类最佳的药物和疫苗组合。截至2024年中报，云顶新耀-B营业总收入3.02亿元、净利润-6.32亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/11131446247950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1574","BK1583","01952"],"gpt_icon":0},{"id":"2490800779","title":"云顶新耀-B盘中异动 下午盘股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490800779","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490800779?lang=zh_cn&edition=full","pubTime":"2024-12-11 13:14","pubTimestamp":1733894042,"startTime":"0","endTime":"0","summary":"2024年12月11日下午盘13时14分，云顶新耀-B股票出现异动，股价急速拉升5.09%。截至发稿，该股报48.500港元/股，成交量277.445万股，换手率0.85%，振幅5.74%。云顶新耀-B股票所在的生物技术行业中，整体跌幅为0.44%。其相关个股中，科济药业-B、北海康成-B、思路迪医药股份涨幅较大，振幅较大的相关个股有北海康成-B、科济药业-B、创胜集团-B，振幅分别为45.77%、23.53%、14.29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211131403984b397a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211131403984b397a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","BK1161","01952"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":0.029},{"period":"1month","weight":0.4406},{"period":"3month","weight":1.1703},{"period":"6month","weight":1.5101},{"period":"1year","weight":1.6749},{"period":"ytd","weight":1.378}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.043978},{"month":2,"riseRate":0.25,"avgChangeRate":0.025861},{"month":3,"riseRate":0.25,"avgChangeRate":-0.030941},{"month":4,"riseRate":0.25,"avgChangeRate":-0.098869},{"month":5,"riseRate":0.5,"avgChangeRate":-0.010924},{"month":6,"riseRate":0.75,"avgChangeRate":0.281644},{"month":7,"riseRate":0,"avgChangeRate":-0.15054},{"month":8,"riseRate":0.25,"avgChangeRate":-0.139716},{"month":9,"riseRate":0.75,"avgChangeRate":0.086225},{"month":10,"riseRate":0.5,"avgChangeRate":0.00246},{"month":11,"riseRate":0.6,"avgChangeRate":0.110884},{"month":12,"riseRate":0.8,"avgChangeRate":0.208873}],"exchange":"SEHK","name":"云顶新耀-B","nameEN":"EVEREST MED-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀-B,01952,云顶新耀-B股票,云顶新耀-B股票老虎,云顶新耀-B股票老虎国际,云顶新耀-B行情,云顶新耀-B股票行情,云顶新耀-B股价,云顶新耀-B股市,云顶新耀-B股票价格,云顶新耀-B股票交易,云顶新耀-B股票购买,云顶新耀-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}